德琪醫藥(06996.HK)與Calithera簽訂全球獨家授權協議
德琪醫藥-B(06996.HK)公布,與專注研發治療腫瘤等危及生命疾病的新型小分子藥物的臨床階段生物技術公司-Calithera就Calithera的CD73小分子抑制劑CB-708的開發及商業化訂立全球獨家授權協議。
根據協議,Calithera將獲得一筆首付款及潛在的開發、註冊和銷售的里程碑付款,總共最多2.55億美元,並有資格就授權產品的銷售獲得單位數至低雙位數百分點的分級特許權使用費。
CB-708是一款高效、選擇性的口服CD73抑制劑,有望在治療多種腫瘤的單藥或聯合療法中釋放巨大潛力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.